<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, 300 studies are underway examining various therapeutic options with the aim of determining which is the most suitable and most appropriate in the treatment of COVID-19 (
 <xref rid="ref20" ref-type="bibr">20</xref>). Under the auspices of the World Health Organization (WHO), several large studies have begun, including the Discovery study. The study will include 3200 patients. Patients are divided into five groups and receive standard therapy given for SARS-CoV2, antiviral therapy and, among others, the much-lauded hydroxychloroquine. A large Solidarity study is also underway, also sponsored by the WHO. In Solidarity study several therapeutic options are compared, namely remdesivir, lopinavir/ritonavir, lopinavir/ritonavir in combination with interferon beta-1; and chloroquine or hydroxychloroquine.
</p>
